Search tips
Search criteria


Important Notice

PubMed Central Canada to be taken offline in February 2018

On February 23, 2018, PubMed Central Canada (PMC Canada) will be taken offline permanently. No author manuscripts will be deleted, and the approximately 2,900 manuscripts authored by Canadian Institutes of Health Research (CIHR)-funded researchers currently in the archive will be copied to the National Research Council’s (NRC) Digital Repository over the coming months. These manuscripts along with all other content will also remain publicly searchable on PubMed Central (US) and Europe PubMed Central, meaning such manuscripts will continue to be compliant with the Tri-Agency Open Access Policy on Publications.

Read more

Results 1-1 (1)

Clipboard (0)
Year of Publication
Document Types
1.  Pharmacokinetic and clinical considerations in the choice of a hypnotic 
British Journal of Clinical Pharmacology  1983;16(Suppl 1):5S-10S.
1 Not only has insomnia become much more frequent in the last hundred years but its causes have also changed considerably.
2 In the treatment of insomnia, benzodiazepines—because of their additional anxiolytic effect—offer substantial advantages over other sleep-inducing agents.
3 The residual fraction—the quotient of plasma concentration at 12 h after drug intake to maximum plasma concentration—makes it possible to differentiate between the benzodiazepines according to their suitability as anxiolytics or hypnotics.
4 Midazolam has the lowest residual fraction of all known benzodiazepines and thus, administered in the appropriate dosage, also has the shortest duration of activity.
PMCID: PMC1428092  PMID: 6138081

Results 1-1 (1)